Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 3/20 | 0.40 |
| ▸ | HTR6 | P50406 | 3/20 | 0.40 |
| ▸ | CDK9 | P50750 | 4/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.39 |
| ▸ | QDPR | P09417 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20760832 | 0.86 | VNN1 (0.44) | VNN1HTR6CDK9CCNT1QDPR | |
| SCHEMBL20760419 | 0.84 | CDK9 (0.45) | SCN9AHTR6CDK9CCNT1HTR2A | |
| SCHEMBL29766145 | 0.83 | RXFP1 (0.48) | RXFP1VNN1HTR6PDE10AHTR2C | |
| SCHEMBL20760556 | 0.83 | CCNT1 (0.41) | VNN1HTR6CDK9CCNT1SIGMAR1 | |
| SCHEMBL29766129 | 0.83 | CCNT1 (0.41) | VNN1HTR6CDK9CCNT1SIGMAR1 | |
| SCHEMBL15001472 | 0.79 | HRH3 (0.46) | HTR6CDK9CCNT1QDPRSIGMAR1 | |
| SCHEMBL29531318 | 0.78 | GABRP (0.49) | CDK9CCNT1QDPRSIGMAR1HTR2C | |
| SCHEMBL24335744 | 0.73 | HTR2C (0.38) | SCN9AHTR6CDK9CCNT1SIGMAR1 | |
| SCHEMBL28368651 | 0.73 | NPC1 (0.44) | NPC1RXFP1LTA4HVNN1SIGMAR1 | |
| SCHEMBL18121751 | 0.71 | HTR2C (0.53) | SCN9AQDPRSIGMAR1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240010652-A1 | COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | BLUEPRINT MEDICINES CORPORATION | 2024-01-11 | — | — | US | disclosed |
| CN-117098760-A | Compositions and methods for treating KIT and PDGFRA mediated diseases | 缆图药品公司 | 2023-11-21 | — | — | CN | disclosed |
| EP-4229060-A1 | COMPOSITIONS AND METHODS FOR TREATING KIT-AND PDGFRA-MEDIATED DISEASES | Blueprint Medicines Corporation (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-110891953-B | Pyrrolotriazines derivatives, preparation method and application thereof | 浙江海正药业股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2022081627-A1 | COMPOSITIONS AND METHODS FOR TREATING KIT-AND PDGFRA-MEDIATED DISEASES | BLUEPRINT MEDICINES CORPORATION (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2019034128-A1 | PYRROLOTRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | 浙江海正药业股份有限公司 | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240010652-A1 | COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | KIT, PDGFRA, PDGFRB | NPC1 294/4885RXFP1 2091/4885SCN9A 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.